Tag: denosumab

1. Bisphosphonates and denosumab increased bone mineral density (BMD) in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, with denosumab also showing some evidence of vertebral fracture reduction. 2. Three trials for lifestyle intervention showed no statistically significant difference in BMD compared to exercise and standard care. Evidence Rating...
1. This systematic review demonstrated that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a significantly reduced risk of vertebral and nonvertebral fractures, compared to placebo. 2. The comparative effectiveness of the different pharmacological agents available to treat osteoporosis is unclear. Evidence Rating Level: 1 (Excellent)...